Olaf Groß
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Olaf Groß has a total of 737 co-authors. Here are the top co-authors by number of shared publications:
- Jürgen Ruland
Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine and Health, Technical University of Munich, Munich, Germany.
19 shared publications - Oliver Gorka
Institute of Neuropathology, Medical Center–University of Freiburg/Medical Faculty - University of Freiburg, Freiburg, Germany
15 shared publications Christina J. Groß
Center for Integrative Biological Signalling Studies (CIBSS), University of Freiburg, Freiburg, Germany
10 shared publications- Svenja Wöhrle
Institute of Neuropathology, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany; Faculty of Biology, University of Freiburg, Freiburg, Germany
10 shared publications Christian Peschel
III. Medical Department for Hematology and Oncology, Klinikum rechts der Isar, Technische Universität München, 81675 München, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
7 shared publicationsTamara Ćiković
Institute of Neuropathology, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany
7 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in Journal of Molecular Biology
- p. 169960
NEK7 Accelerates NLRP3 Inflammasome Activation
- 29 July 2026
- Published by Elsevier in Journal of Molecular Biology
- p. 169960
Open AccessNEK7 Accelerates NLRP3 Inflammasome Activation
- Open Access
- 13 May 2026
- Vol. 2 (4)
FAS-controlled T cells drive lymphoproliferation through glycolysis without effector differentiation
In FAS deficiency, lymphoproliferation is driven by FAS-controlled T cells (FCT), yet underlying metabolic programs remain unclear. Using EBV-activated effector T cells as a benchmark, Maccari et al. show that FCT display comparably heightened glycolysis, but a metabolic program uncoupled from T-BET expression and IFNγ production.
- 13 May 2026
- Vol. 2 (4)
Open AccessFAS-controlled T cells drive lymphoproliferation through glycolysis without effector differentiation
In FAS deficiency, lymphoproliferation is driven by FAS-controlled T cells (FCT), yet underlying metabolic programs remain unclear. Using EBV-activated effector T cells as a benchmark, Maccari et al. show that FCT display comparably heightened glycolysis, but a metabolic program uncoupled from T-BET expression and IFNγ production.
- Open Access
- 22 March 2026
- Published by Elsevier in SSRN Electronic Journal
NEK7 accelerates NLRP3 inflammasome activation
SummaryThe NLRP3 inflammasome is a major driver of immunopathology, making it a sought-after drug target. In spite of two decades of intense research, its activation mechanism is still poorly understood, impeding inhibitor design. NEK7 was reported to be essential for NLRP3 activation, and several newly identified NLRP3 inhibitors were suggested to act by interfering with their interaction. Here we report that NEK7 accelerates, but is in principle dispensable for NLRP3 activation. The onset of inflammasome activation on the single-cell level was unaltered in the absence of NEK7, yet the rate of cells to undergo inflammasome formation and subsequent pyroptosis was approximately 4-fold reduced. Therefore, therapeutic targeting of the NEK7-NLRP3 interaction might have an incomplete effect, which has to be considered for drug development. We confirmed entrectinib as a NEK7-dependent inhibitor, while other published drug candidates turned out not to rely on its presence. Our results support two possible scenarios for the role of NEK7 in NLRP3 activation: either, NEK7 accelerates one unique pathway of NLRP3 activation, or it is essential for a first, fast pathway, while being dispensable for a second, slower NLRP3 activation pathway.
- 22 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNEK7 accelerates NLRP3 inflammasome activation
SummaryThe NLRP3 inflammasome is a major driver of immunopathology, making it a sought-after drug target. In spite of two decades of intense research, its activation mechanism is still poorly understood, impeding inhibitor design. NEK7 was reported to be essential for NLRP3 activation, and several newly identified NLRP3 inhibitors were suggested to act by interfering with their interaction. Here we report that NEK7 accelerates, but is in principle dispensable for NLRP3 activation. The onset of inflammasome activation on the single-cell level was unaltered in the absence of NEK7, yet the rate of cells to undergo inflammasome formation and subsequent pyroptosis was approximately 4-fold reduced. Therefore, therapeutic targeting of the NEK7-NLRP3 interaction might have an incomplete effect, which has to be considered for drug development. We confirmed entrectinib as a NEK7-dependent inhibitor, while other published drug candidates turned out not to rely on its presence. Our results support two possible scenarios for the role of NEK7 in NLRP3 activation: either, NEK7 accelerates one unique pathway of NLRP3 activation, or it is essential for a first, fast pathway, while being dispensable for a second, slower NLRP3 activation pathway.
- Open Access
- 3 February 2026
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (8) , 1570-1584
The second mitochondrial activator of caspases (SMAC) regulates growth, inflammation and mitochondrial integrity in cancer cells
SMAC is a mitochondrial intermembrane space protein, which is released during apoptosis and whose known function is antagonism of inhibitor of apoptosis proteins in the cytosol, to facilitate caspase activation. Recent data suggest that SMAC can also be released by sub-lethal signals in the apoptosis pathway, in the absence of cell death. We here explored potential functions of SMAC in non-apoptotic cells. We found that a portion of SMAC is spontaneously released into the cytosol in the absence of apoptosis, regulated by the BCL-2-family proteins BAX and BAK and the fission GTPase DRP1. In cancer cell lines, SMAC was required for the activation of caspases in lethal and non-lethal conditions, while this contribution to caspase-activation was much smaller in non-malignant fibroblast lines. In cells with high levels of cytosolic SMAC, SMAC deficiency reduced in vitro migration, invasion and anchorage-independent growth as well as metastasis in a xenograft model in zebrafish. SMAC-deficient cells further showed a reduced activity in interferon signaling, associated with reduced cytosolic presence of mitochondrial DNA and activation of the stimulator of interferon genes (STING), and SMAC expression levels correlated with interferon-induced genes in cancer data sets. We further found that SMAC can regulate mitochondrial morphology and integrity. Finally, high gene-expression of SMAC was associated with poor prognosis in patients of several cancer types. These results identify SMAC as a regulator of inflammation and growth behavior of cancer cells. They further report a mitochondrial function of SMAC and demonstrate a role of SMAC in human cancer biology across several cancer entities.
- 3 February 2026
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (8) , 1570-1584
Open AccessThe second mitochondrial activator of caspases (SMAC) regulates growth, inflammation and mitochondrial integrity in cancer cells
SMAC is a mitochondrial intermembrane space protein, which is released during apoptosis and whose known function is antagonism of inhibitor of apoptosis proteins in the cytosol, to facilitate caspase activation. Recent data suggest that SMAC can also be released by sub-lethal signals in the apoptosis pathway, in the absence of cell death. We here explored potential functions of SMAC in non-apoptotic cells. We found that a portion of SMAC is spontaneously released into the cytosol in the absence of apoptosis, regulated by the BCL-2-family proteins BAX and BAK and the fission GTPase DRP1. In cancer cell lines, SMAC was required for the activation of caspases in lethal and non-lethal conditions, while this contribution to caspase-activation was much smaller in non-malignant fibroblast lines. In cells with high levels of cytosolic SMAC, SMAC deficiency reduced in vitro migration, invasion and anchorage-independent growth as well as metastasis in a xenograft model in zebrafish. SMAC-deficient cells further showed a reduced activity in interferon signaling, associated with reduced cytosolic presence of mitochondrial DNA and activation of the stimulator of interferon genes (STING), and SMAC expression levels correlated with interferon-induced genes in cancer data sets. We further found that SMAC can regulate mitochondrial morphology and integrity. Finally, high gene-expression of SMAC was associated with poor prognosis in patients of several cancer types. These results identify SMAC as a regulator of inflammation and growth behavior of cancer cells. They further report a mitochondrial function of SMAC and demonstrate a role of SMAC in human cancer biology across several cancer entities.
- Open Access
- 5 December 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (12) , 1543-1545
Externalized Inflammasomes in Visceral Fat Sustain Obesity-Related Inflammation
- 5 December 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (12) , 1543-1545
Open AccessExternalized Inflammasomes in Visceral Fat Sustain Obesity-Related Inflammation
- Open Access
- 20 November 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e73822
Identifying Biomedical Entities for Datasets in Scientific Articles: 4-Step Cache-Augmented Generation Approach Using GPT-4o and PubTator 3.0
Background: The accurate extraction of biomedical entities in scientific articles is essential for effective metadata annotation of research datasets, ensuring data findability, accessibility, interoperability, and reusability in collaborative research. Objective: This study aimed to introduce a novel 4-step cache-augmented generation approach to identify biomedical entities for an automated metadata annotation of datasets, leveraging GPT-4o and PubTator 3.0. Methods: The method integrates four steps: (1) generation of candidate entities using GPT-4o, (2) validation via PubTator 3.0, (3) term extraction based on a metadata schema developed for the specific research area, and (4) a combined evaluation of PubTator-validated and schema-related terms. Applied to 23 articles published in the context of the Collaborative Research Center OncoEscape , the process was validated through supervised, face-to-face interviews with article authors, allowing an assessment of annotation precision using random-effects meta-analysis. Results: The approach yielded a mean of schema-related and PubTator-validated biomedical entities per article. Within the study’s specific context, the overall annotation precision was 98% (95% CI 94%-100%), with most prediction errors concentrated in articles outside the primary basic research domain of the schema. In a subsample (n=20), available supplemental material was included in the prediction process, but it did not improve precision (98%, 95% CI 95%‐100%). Moreover, the mean number of schema-related entities was ( P =.56) and the mean number of PubTator-validated entities was ( P =.68); these values did not increase with the additional information provided in the supplement. Conclusions: This study highlights the potential of large language model–supported metadata annotation. The findings underscore the practical feasibility of full-text analysis and suggest its potential for integration into routine workflows for biomedical metadata generation.
- 20 November 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e73822
Open AccessIdentifying Biomedical Entities for Datasets in Scientific Articles: 4-Step Cache-Augmented Generation Approach Using GPT-4o and PubTator 3.0
Background: The accurate extraction of biomedical entities in scientific articles is essential for effective metadata annotation of research datasets, ensuring data findability, accessibility, interoperability, and reusability in collaborative research. Objective: This study aimed to introduce a novel 4-step cache-augmented generation approach to identify biomedical entities for an automated metadata annotation of datasets, leveraging GPT-4o and PubTator 3.0. Methods: The method integrates four steps: (1) generation of candidate entities using GPT-4o, (2) validation via PubTator 3.0, (3) term extraction based on a metadata schema developed for the specific research area, and (4) a combined evaluation of PubTator-validated and schema-related terms. Applied to 23 articles published in the context of the Collaborative Research Center OncoEscape , the process was validated through supervised, face-to-face interviews with article authors, allowing an assessment of annotation precision using random-effects meta-analysis. Results: The approach yielded a mean of schema-related and PubTator-validated biomedical entities per article. Within the study’s specific context, the overall annotation precision was 98% (95% CI 94%-100%), with most prediction errors concentrated in articles outside the primary basic research domain of the schema. In a subsample (n=20), available supplemental material was included in the prediction process, but it did not improve precision (98%, 95% CI 95%‐100%). Moreover, the mean number of schema-related entities was ( P =.56) and the mean number of PubTator-validated entities was ( P =.68); these values did not increase with the additional information provided in the supplement. Conclusions: This study highlights the potential of large language model–supported metadata annotation. The findings underscore the practical feasibility of full-text analysis and suggest its potential for integration into routine workflows for biomedical metadata generation.
- Open Access
NEK7 accelerates NLRP3 inflammasome activation
Summary: The NLRP3 inflammasome is a major driver of immunopathology, making it a sought-after drug target. In spite of two decades of intense research, its precise activation mechanism remains elusive, impeding inhibitor design. NEK7 was reported as essential for NLRP3 activation, and several newly identified inhibitors were suggested to act by interfering with their interaction. Here we report that NEK7 accelerates, but is in principle dispensable for NLRP3 activation. The onset of inflammasome activation was unaltered in the absence of NEK7, yet the rate of cells to undergo inflammasome formation and subsequent pyroptosis was approximately 4-fold reduced. Therefore, therapeutic targeting of the NEK7-NLRP3 interaction might have an incomplete effect, which should be considered for drug development. We confirmed entrectinib as a NEK7-dependent inhibitor, while other published compounds turned out not to rely on it. Our results support two possible scenarios for the role of NEK7 in NLRP3 activation: either, NEK7 accelerates one unique pathway of NLRP3 activation, or it is essential for a fast pathway, while being dispensable for a second, slower mode of NLRP3 activation.
Open AccessNEK7 accelerates NLRP3 inflammasome activation
Summary: The NLRP3 inflammasome is a major driver of immunopathology, making it a sought-after drug target. In spite of two decades of intense research, its precise activation mechanism remains elusive, impeding inhibitor design. NEK7 was reported as essential for NLRP3 activation, and several newly identified inhibitors were suggested to act by interfering with their interaction. Here we report that NEK7 accelerates, but is in principle dispensable for NLRP3 activation. The onset of inflammasome activation was unaltered in the absence of NEK7, yet the rate of cells to undergo inflammasome formation and subsequent pyroptosis was approximately 4-fold reduced. Therefore, therapeutic targeting of the NEK7-NLRP3 interaction might have an incomplete effect, which should be considered for drug development. We confirmed entrectinib as a NEK7-dependent inhibitor, while other published compounds turned out not to rely on it. Our results support two possible scenarios for the role of NEK7 in NLRP3 activation: either, NEK7 accelerates one unique pathway of NLRP3 activation, or it is essential for a fast pathway, while being dispensable for a second, slower mode of NLRP3 activation.
- Open Access
- 16 September 2025
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 120 (6) , 1141-1154
NLRP3 mediates lipid-driven macrophage proliferation in established atherosclerosis
An increased number of macrophages in the atherosclerotic plaque is associated with plaque instability and plaque progression. Lowering systemic cholesterol levels suppresses local macrophage proliferation and leads to plaque regression. However, the pathways regulating macrophage proliferation remain poorly understood. We investigated the cellular processes that underlie lipid-triggered local macrophage proliferation in the atherosclerotic plaque in transgenic mice and in human plaque tissue samples. Macrophages from mice with genetic deficiencies in scavenger receptors Cd36 −/− and Msr1 −/− showed reduced lipid uptake, lower intracellular lipid content, and lower proliferation compared to wild type macrophages. Double knockouts for the cholesterol exporters Abca1 and Abcg1 (MAC-ABC-DKO) showed increased rates of macrophage proliferation and apoptosis. In Cd36 −/− , Msr1 −/− , and MAC-ABC-DKO mixed bone marrow chimeras, no differences in chimerism were observed in blood or aorta after 4 weeks on a high-cholesterol diet. After 12 weeks of atherogenic diet, wild type macrophages predominated in the aorta since they proliferated more than neighboring Cd36 −/− or Msr1 −/− macrophages, and were less apoptotic than ABC-DKO macrophages, respectively. Knockout of NLRP3, but not ASC, Caspase 1 or IL-1 receptor, limited macrophage proliferation; indicating an NLRP3-dependent, but inflammasome-independent, effect. Inhibition of NLRP3 by MCC950 in human carotid artery plaque tissue cultures resulted in the suppression of intra-plaque macrophage proliferation and IL-1β release consistent with murine in vivo data. We identified a novel role for NLRP3 in driving macrophage proliferation in atherosclerotic plaques. NLRP3 inhibition may represent an ideal therapeutic target in atherosclerosis by combining anti-inflammasome and anti-proliferative effects in macrophages.
- 16 September 2025
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 120 (6) , 1141-1154
Open AccessNLRP3 mediates lipid-driven macrophage proliferation in established atherosclerosis
An increased number of macrophages in the atherosclerotic plaque is associated with plaque instability and plaque progression. Lowering systemic cholesterol levels suppresses local macrophage proliferation and leads to plaque regression. However, the pathways regulating macrophage proliferation remain poorly understood. We investigated the cellular processes that underlie lipid-triggered local macrophage proliferation in the atherosclerotic plaque in transgenic mice and in human plaque tissue samples. Macrophages from mice with genetic deficiencies in scavenger receptors Cd36 −/− and Msr1 −/− showed reduced lipid uptake, lower intracellular lipid content, and lower proliferation compared to wild type macrophages. Double knockouts for the cholesterol exporters Abca1 and Abcg1 (MAC-ABC-DKO) showed increased rates of macrophage proliferation and apoptosis. In Cd36 −/− , Msr1 −/− , and MAC-ABC-DKO mixed bone marrow chimeras, no differences in chimerism were observed in blood or aorta after 4 weeks on a high-cholesterol diet. After 12 weeks of atherogenic diet, wild type macrophages predominated in the aorta since they proliferated more than neighboring Cd36 −/− or Msr1 −/− macrophages, and were less apoptotic than ABC-DKO macrophages, respectively. Knockout of NLRP3, but not ASC, Caspase 1 or IL-1 receptor, limited macrophage proliferation; indicating an NLRP3-dependent, but inflammasome-independent, effect. Inhibition of NLRP3 by MCC950 in human carotid artery plaque tissue cultures resulted in the suppression of intra-plaque macrophage proliferation and IL-1β release consistent with murine in vivo data. We identified a novel role for NLRP3 in driving macrophage proliferation in atherosclerotic plaques. NLRP3 inhibition may represent an ideal therapeutic target in atherosclerosis by combining anti-inflammasome and anti-proliferative effects in macrophages.
- Top Cited PapersOpen Access
Acute suppression of mitochondrial ATP production prevents apoptosis and provides an essential signal for NLRP3 inflammasome activation
- Open Access
- 18 November 2024
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 40 (12)
Dynamic modelling of signalling pathways when ordinary differential equations are not feasible
Mathematical modelling plays a crucial role in understanding inter- and intracellular signalling processes. Currently, ordinary differential equations (ODEs) are the predominant approach in systems biology for modelling such pathways. While ODE models offer mechanistic interpretability, they also suffer from limitations, including the need to consider all relevant compounds, resulting in large models difficult to handle numerically and requiring extensive data. In previous work, we introduced the retarded transient function (RTF) as an alternative method for modelling temporal responses of signalling pathways. Here, we extend the RTF approach to integrate concentration or dose-dependencies into the modelling of dynamics. With this advancement, RTF modelling now fully encompasses the application range of ordinary differential equation (ODE) models, which comprises predictions in both time and concentration domains. Moreover, characterizing dose-dependencies provides an intuitive way to investigate and characterize signalling differences between biological conditions or cell-types based on their response to stimulating inputs. To demonstrate the applicability of our extended approach, we employ data from time- and dose-dependent inflammasome activation in bone-marrow derived macrophages (BMDMs) treated with nigericin sodium salt. Our results show the effectiveness of the extended RTF approach as a generic framework for modelling dose-dependent kinetics in cellular signalling. The approach results in intuitively interpretable parameters that describe signal dynamics and enables predictive modelling of time- and dose-dependencies even if only individual cellular components are quantified. The presented approach is available within the MATLAB-based Data2Dynamics modelling toolbox at https://github.com/Data2Dynamics and https://zenodo.org/records/14008247 and as R code at https://github.com/kreutz-lab/RTF.
- 18 November 2024
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 40 (12)
Open AccessDynamic modelling of signalling pathways when ordinary differential equations are not feasible
Mathematical modelling plays a crucial role in understanding inter- and intracellular signalling processes. Currently, ordinary differential equations (ODEs) are the predominant approach in systems biology for modelling such pathways. While ODE models offer mechanistic interpretability, they also suffer from limitations, including the need to consider all relevant compounds, resulting in large models difficult to handle numerically and requiring extensive data. In previous work, we introduced the retarded transient function (RTF) as an alternative method for modelling temporal responses of signalling pathways. Here, we extend the RTF approach to integrate concentration or dose-dependencies into the modelling of dynamics. With this advancement, RTF modelling now fully encompasses the application range of ordinary differential equation (ODE) models, which comprises predictions in both time and concentration domains. Moreover, characterizing dose-dependencies provides an intuitive way to investigate and characterize signalling differences between biological conditions or cell-types based on their response to stimulating inputs. To demonstrate the applicability of our extended approach, we employ data from time- and dose-dependent inflammasome activation in bone-marrow derived macrophages (BMDMs) treated with nigericin sodium salt. Our results show the effectiveness of the extended RTF approach as a generic framework for modelling dose-dependent kinetics in cellular signalling. The approach results in intuitively interpretable parameters that describe signal dynamics and enables predictive modelling of time- and dose-dependencies even if only individual cellular components are quantified. The presented approach is available within the MATLAB-based Data2Dynamics modelling toolbox at https://github.com/Data2Dynamics and https://zenodo.org/records/14008247 and as R code at https://github.com/kreutz-lab/RTF.